Issued 2026-08-13 at $17.23 · now $16.50 (2026-08-13, −4.2% since)
Based on its own history, a month from the 2026-08-13 close, MLTX has typically landed between $13.60 and $24.11 — a range of −21.1% to +39.9% from the issuance price $17.23.
- Actual close
- Typical path (median)
- Middle 50% of outcomes
- 90% range
1,437 overlapping 1 month windows · 2020-10-20 – 2026-07-15 · basis climatology · forecast (batch). Probability up 53.8% (90% CI 51.6–56.0%, ≈1,400 obs).
The cone is anchored at the 2026-08-13 issuance close ($17.23) — the price the forecast resolves against on 2026-09-11, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.
Where MLTX has typically landed a month from the 2026-08-13 close of $17.23 — the range is history, not a prediction.
- now $16.5 (-4.2%)
- typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $17.43 (+1.1%)
- middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $15.9–$18.95
- 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $13.6–$24.11
| Start | Return | Max drop | Max rise |
|---|---|---|---|
| 3 worst | |||
| 2025-08-29 | −87.3% | −87.3% | +11.2% |
| 2025-09-02 | −87.3% | −87.9% | +5.9% |
| 2025-08-28 | −86.9% | −86.9% | +13.1% |
| 3 best | |||
| 2023-06-23 | +128.0% | +0.0% | +128.0% |
| 2023-06-13 | +124.4% | +0.0% | +124.4% |
| 2023-06-14 | +117.9% | −3.5% | +117.9% |
1,437 overlapping windows · 2020-10-20 – 2026-08-13 · not cherry-picked
Pending catalysts
- 2026-09-28 — Trial primary completion: Phase 3 primary completion: An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN) (source, as of 2026-08-14)
- 2027-01-15 — Trial primary completion: Phase 3 primary completion: Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response (source, as of 2026-08-14)
- 2027-02-04 — Trial primary completion: Phase 3 primary completion: Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug (source, as of 2026-08-14)
- 2028-02-04 — Trial primary completion: Phase 3 primary completion: A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis (source, as of 2026-08-14)
- 2028-06-13 — Trial primary completion: Phase 3 primary completion: A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa (source, as of 2026-08-14)
Public, scheduled events — dated attention, not a prediction of the outcome. See the FDA catalysts page for the historical base rate.
Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.
iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~6 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.Up-frequency and average month-over-month return · historical frequency, not a prediction
Company insiders iOpen-market share purchases and sales by the company's own officers and directors, by filing date.
Last 90 days · as of 2026-08-13 · point-in-time by filing date
No insider transactions on record in the last 90 days.
Congressional disclosures
No congressional trades disclosed for this company.
Research tool, not investment advice — historical frequencies, not recommendations. Full terms.